• Virtuix Holdings Inc. expanded into healthcare research through a collaboration with Rutgers University on AI-assisted neurodivergent therapy using its Omni One platform.
• Rutgers deployed Omni One at WINLAB to study movement-centered XR with adaptive AI for behavioral therapy applications, including autism therapy for children.
• Research will track engagement metrics such as attention, movement patterns, response timing, engagement consistency, and spatial interaction over time.
• Move broadens Omni One beyond consumer entertainment and defense, following a recent university deployment for rehabilitation and clinical simulation evaluation.
• Fortune Business Insights projects the ASD treatment market to grow to more than $18 billion by 2034 from about $9.2 billion in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virtuix Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-062908), on May 29, 2026, and is solely responsible for the information contained therein.